GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rua Bioscience Ltd (NZSE:RUA) » Definitions » Operating Income

Rua Bioscience (NZSE:RUA) Operating Income : NZ$-5.25 Mil (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Rua Bioscience Operating Income?

Rua Bioscience's Operating Income for the six months ended in Jun. 2024 was NZ$-2.80 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2024 was NZ$-5.25 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Rua Bioscience's Operating Income for the six months ended in Jun. 2024 was NZ$-2.80 Mil. Rua Bioscience's Revenue for the six months ended in Jun. 2024 was NZ$0.07 Mil. Therefore, Rua Bioscience's Operating Margin % for the quarter that ended in Jun. 2024 was -4,063.77%.

Rua Bioscience's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Rua Bioscience's annualized ROC % for the quarter that ended in Jun. 2024 was -82.37%. Rua Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -134.47%.


Rua Bioscience Operating Income Historical Data

The historical data trend for Rua Bioscience's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rua Bioscience Operating Income Chart

Rua Bioscience Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Operating Income
-7.13 -9.02 -13.00 -5.25

Rua Bioscience Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Operating Income Get a 7-Day Free Trial -5.14 -3.66 -9.34 -2.45 -2.80

Rua Bioscience Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NZ$-5.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rua Bioscience  (NZSE:RUA) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Rua Bioscience's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-5.608 * ( 1 - 0% )/( (7.325 + 6.291)/ 2 )
=-5.608/6.808
=-82.37 %

where

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Rua Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-5.608/( ( (2.912 + max(1.956, 0)) + (2.653 + max(0.82, 0)) )/ 2 )
=-5.608/( ( 4.868 + 3.473 )/ 2 )
=-5.608/4.1705
=-134.47 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.126 + 0.249 + 1.968) - (0.206 + 0 + 0.181)
=1.956

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.278 + 1.367) - (0.554 + 0 + 0.271)
=0.82

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Rua Bioscience's Operating Margin % for the quarter that ended in Jun. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-2.804/0.069
=-4,063.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Rua Bioscience Operating Income Related Terms

Thank you for viewing the detailed overview of Rua Bioscience's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Rua Bioscience Business Description

Traded in Other Exchanges
N/A
Address
1 Commerce Place, Awapuni, Gisborne, NZL, 4071
Rua Bioscience Ltd is a pharmaceutical company engaged in the production of cannabinoid medicines. The company caters to both domestic and international customers. It operates in one segment, being research and development and the sale of pharmaceutical products in Australia, Germany and New Zealand.

Rua Bioscience Headlines

No Headlines